The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 06, 2026

Filed:

Dec. 19, 2019
Applicant:

Roche Diagnostics Operations, Inc., Indianapolis, IN (US);

Inventors:

Roberto Latini, Milan, IT;

Serge Masson, Monza, IT;

Dirk Block, Bichl, DE;

Christian Zaugg, Rheinfelden, CH;

Thomas Dieterle, Freiburg, DE;

Edelgard Kaiser, Huenenberg See, CH;

Johann Karl, Peissenberg, DE;

Vinzent Rolny, Munich, DE;

Ursula-Henrike Wienhues-Thelen, Krailing, DE;

Assignee:

Roche Diagnostics Operations, Inc., Indianapolis, IN (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/53 (2006.01); G01N 33/68 (2006.01);
U.S. Cl.
CPC ...
G01N 33/6893 (2013.01); G01N 2333/4703 (2013.01); G01N 2333/4712 (2013.01); G01N 2333/4745 (2013.01); G01N 2333/475 (2013.01); G01N 2333/495 (2013.01); G01N 2333/50 (2013.01); G01N 2333/515 (2013.01); G01N 2333/58 (2013.01); G01N 2333/70525 (2013.01); G01N 2800/325 (2013.01);
Abstract

Methods for predicting the risk of a subject of rapidly progressing to chronic heart failure and/or of hospitalization due to chronic heart failure and/or death are disclosed. The method is based on the determination of at least one biomarker selected from the group consisting of a BNP-type peptide, IGFBP7 (IGF binding protein 7), a cardiac Troponin, soluble ST2 (sST2), FGF-23 (Fibroblast Growth Factor 23), and Growth Differentiation Factor 15 (GDF-15), in a sample of a subject. The method may further encompass the assessment of the presence or absence of (i) abnormal midwall fractional shortening or (ii) left ventricular hypertrophy. Further envisaged by the present invention are devices adapted to carry out the present invention.


Find Patent Forward Citations

Loading…